SULLIVAN CHRISTOPHER RYAN (Interim CFO) sold 20.3% of their position (10.19K shares) of AVALO THERAPEUTICS, INC. on the open market
Open‑market sale worth $179.5K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/11/2026ACC: 0001810417-26-000021
Officer· Interim CFO
Since Apr 2020
-10.19K
Net shares
Net seller
$179.5K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
10.19K acquired · 20.37K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+10.19K
Price / share
$8.04
Trade value
$81.89K
% of position
25.5%
9/10/2026
39.90K→50.09K
Common Stock
Direct
Shares
−10.19K
Price / share
$17.62
Trade value
$179.46K
% of position
20.3%
9/10/2026
50.09K→39.90K
Total
Net shares
+0.00
Net value
-$97.57K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/10/2026 | M · Option Exercise | +10.19K | $8.04 | $81.89K | 25.5% | 39.90K | 50.09K |
| Common Stock Direct | 9/10/2026 | S · Sale | −10.19K | $17.62 | $179.46K | 20.3% | 50.09K | 39.90K |
| Total | +0.00 | -$97.57K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
10.19K shares
Shares
−10.19K
Strike price
8.04
Held after
105.81K
Exercisable
—
9/10/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock10.19K shares | 9/10/2026 | M · Option Exercise | −10.19K | 8.04 | — | 105.81K |